


**IN THE CLAIMS:**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Currently Amended) An S-nitrosothiol derivative of penicillamine or glutathione of formula I:



or its pharmaceutically acceptable salt thereof,

in which:


A and B are phenyl groups or together form the group  $-\text{CH}_2\text{-Q-CH}_2-$  constituting a six membered ring in which Q represents oxygen, sulfur, or a group  $\text{N-R}^3$ , in which  $\text{R}^3$  is hydrogen or an alkyl group  $\text{C}_1\text{-C}_4$ ;

$\text{R}^1$  is an acyl group, which may be an aliphatic  $\text{C}_1\text{-C}_5$  acyl group or a glutamic acid acyl group bonded via its gamma carboxyl group;

$\text{R}^2$  is a hydroxyl group or a glycine group bonded via a peptide bond;

with the proviso that if  $\text{R}^1$  is an aliphatic acyl group, then  $\text{R}^2$  is a hydroxyl group, and if  $\text{R}^1$  is a glutamic acid acyl group, then  $\text{R}^2$  is a glycine group.

20. (Previously Presented) The S-nitrosothiol derivative of Claim 19 having the formula:




wherein R<sup>4</sup> is a C<sub>1</sub>-C<sub>4</sub> alkyl group.

21. (Previously Presented) The S-nitrosothiol derivative of Claim 19 which is N-acetyl-2-amino-2-[4-(4-S-nitrosomercaptotetrahydropyran)] acetic acid.

22. (Previously Presented) The S-nitrosothiol derivative of Claim 19 which is N-acetyl-2-amino-2-[4-(4-S-nitrosomercapto-1-methylpiperidin)] acetic acid.

23. (Previously Presented) The S-nitrosothiol derivative of Claim 19 which is N-acetyl-2-amino-3-benzyl-3-S-nitrosomercapto-4-phenylbutanoic acid.

24. (Currently Amended) The S-nitrosothiol of Claim 19, having the following formula III:



25. (Previously Presented) The S-nitrosothiol derivative of Claim 19 which is N[N-γ-L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto) tetrahydropyran))acetyl]glycine.

27. (Previously Presented) The S-nitrosothiol derivative of Claim 19 which is N[N-γ-L-glutamyl-2-amino-3-benzyl-3-(S-nitrosomercapto)-4-phenylbutanoyl]glycine.

29. (Currently Amended) A pharmaceutical composition comprising a ~~platelet~~  
~~aggregating-inhibiting~~ an effective amount of the S-nitrosothiol derivatives of Claim 19  
and a pharmaceutical carrier therefor.

CC(C(=O)O)C(=O)N(C(=O)R4)C(C)C(B)C(A)C(S(=O)(=O)O) (II)


H:\work\100\14797\amend\14797.am3.doc

31. (Previously Presented) The pharmaceutical composition according to Claim 29 which is N-acetyl-2-amino-2-[4-(4-S-nitrosomercaptotetrahydropyran)] acetic acid.

32. (Previously Presented) The pharmaceutical composition according to Claim 29 which is N-acetyl-2-amino-2-[4-(4-S-nitrosomercapto-1-methylpiperidin)] acetic acid.

33. (Previously Presented) The pharmaceutical composition according to Claim 29 which is N-acetyl-2-amino-3-benzyl-3-S-nitrosomercapto-4-phenylbutanoic acid.

34. (Previously Presented) The pharmaceutical composition according to Claim 29 wherein the S-nitrosothiol derivative has the formula




35. (Previously Presented) The pharmaceutical composition according to Claim 29 wherein the S-nitrosothiol derivative is N[N-γ-L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto) tetrahydropyran))acetyl]-glycine.

36. (Previously Presented) The pharmaceutical composition according to Claim 29 wherein the S-nitrosothiol derivative is N[N-γ-L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto-1-methylpiperidin))acetyl]glycine.

37. (Previously Presented) The pharmaceutical composition according to Claim 29 wherein the S-nitrosothiol derivative is N[N-γ-L-glutamyl-2-amino-3-benzyl-3-(S-nitrosomercapto)-4-phenylbutanoyl]glycine.

38. (New) The method according to Claim 28 wherein the S-nitrosothiol derivative has the formula:



wherein R<sup>4</sup> is a C<sub>1</sub>-C<sub>4</sub> alkyl group.